Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;47(9):2882-7.
doi: 10.1128/AAC.47.9.2882-2887.2003.

Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients

Peter W Kim  1 , Anthony D Harris, Mary-Claire Roghmann, J Glenn Morris Jr, Arjun Strinivasan, Eli N Perencevich
Affiliations

Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients

Peter W Kim et al. Antimicrob Agents Chemother. 2003 Sep.

Abstract

Antimicrobial resistance is an emerging problem among nosocomial bacteria. Risk factors for the recovery of ceftriaxone-resistant (CRCF) or -susceptible (CSCF) Citrobacter freundii in clinical cultures from hospitalized patients were determined by using a case-case-control study design. CRCF was isolated from 43 patients (case group 1) and CSCF was isolated from 87 patients (case group 2) over a 3-year period. Risk factors for CRCF were exposure to imipenem (odds ratio [OR], 7.5; 95% confidence interval [CI], 1.2 to 45.4), broad-spectrum cephalosporins (OR, 6.9; 95% CI, 1.8 to 26.7), vancomycin (OR, 3.0; 95% CI, 1.2 to 7.4), or piperacillin-tazobactam (OR, 2.6; 95% CI, 1.1 to 6.2), as well as hospital length of stay >or=1 week (OR, 3.6; 95% CI, 1.3 to 10.2) and intensive care unit (ICU) stay (OR, 2.6; 95% CI, 1.1 to 6.2). Risk factors for CSCF were peripheral vascular disease (OR, 23.2; 95% CI, 4.3 to 124.6), AIDS (OR, 9.5; 95% CI, 1.6 to 55.5), cerebrovascular disease (OR, 4.2; 95% CI, 1.6 to 10.8), and ICU stay (OR, 3.1; 95% CI, 1.8 to 5.4).

PubMed Disclaimer

References

    1. Arens, S., and L. Verbist. 1997. Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin. Microbiol. Infect. 3:53-57. - PubMed
    1. Bonten, M. J., S. Slaughter, A. W. Ambergen, M. K. Hayden, J. van Voorhis, C. Nathan, and R. A. Weinstein. 1998. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch. Intern. Med. 158:1127-1132. - PubMed
    1. Brown, E. H., R. C. Spencer, and J. M. Brown. 1990. The emergence of bacterial resistance in hospitals—a need for continuous surveillance. J. Hosp. Infect. 15(Suppl. A):35-39. - PubMed
    1. Burwen, D. R., S. N. Banerjee, and R. P. Gaynes. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance. Syst. J. Infect. Dis. 170:1622-1625. - PubMed
    1. Chen, Y. S., W. W. Wong, C. P. Fung, K. W. Yu, and C. Y. Liu. 2002. Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J. Microbiol. Immunol. Infect. 35:109-114. - PubMed

Publication types

LinkOut - more resources